A Phase 1 interventional study of Furmonertinib and Furmonertinib in Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer and Advanced Non-Small Cell Lung Cancer, sponsored by ArriVent BioPharma, Inc.. Active, not recruiting at 42 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by ArriVent BioPharma, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.
Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is one of 7 that started in 2022, is one of 4 in phase 1, reaches primary completion later than 6 of the 33 other live ones, and was the 9th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Peking University Cancer Hospital & Institute · Sites in China
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–75
Hunan Cancer Hospital · Sites in China
Ages 18+
Guangzhou University of Traditional Chinese Medicine · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 30 · Phase 3 5
First in 2017; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 60 across the 41 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 41 have an industry lead sponsor. The 10 most frequent:
ArriVent BioPharma, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
ArriVent BioPharma, Inc. has 3 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
8 of the studies testing aflutinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04853342Phase 3Allist Pharmaceuticals, Inc.To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | 2026-12 |
| NCT06674343Phase 3Peking Union Medical College HospitalFurmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations | 2026-12-31 |
| NCT06652048Jialei WangHigh-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | 2026-12 |
| NCT06890182Tianjin Medical University Cancer Institute and HospitalFirmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | 2026-12 |
| NCT06192849Juan LI, MDTo Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy | 2026-12-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Key Inclusion Criteria:
Stage 1 dose escalation and backfill cohorts and Stage 2 Cohorts 1, 2, 3 and 4:
-Patients with (including ) may be eligible if meeting additional protocol specified criteria.
Stage 1 Dose Escalation and Backfill Cohorts Inclusion Criteria:
- Documented validated results from local testing of tumor tissue or blood confirming the presence of an activating, including uncommon, EGFR mutation or exon 20 insertion mutation performed at a CLIA-or equivalently certified laboratory.
Stage 2 Cohort 1 Previously Treated, Locally Advanced or Metastatic NSCLC Patients with EGFR Exon 20 Insertion Mutations Inclusion Criteria
Stage 2 Cohort 2 Previously treated, Locally Advanced or Metastatic NSCLC Patients with HER2 Exon 20 Insertion Mutations Inclusion Criteria
Stage 2 Cohort 3 Previously Treated, Locally Advanced or Metastatic NSCLC Patients with EGFR Activating Mutations Mutations, who are not eligible for Cohorts 1 and 4 Inclusion Criteria
Stage 2 Cohort 4 Untreated or Previously Treated EGFR TKI-Naïve, Locally Advanced or Metastatic NSCLC Patients with EGFR Uncommon Mutations excluding EGFR Exon 20 insertions Inclusion Criteria
Key Exclusion Criteria:
Stage 2 Cohort 4 Untreated or Previously Treated EGFR TKI-Naïve, Locally Advanced or Metastatic NSCLC Patients with EGFR Uncommon Mutations Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental: Previously treated patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations
Drug: Furmonertinib
Previously Treated NSCLC Patients with EGFR Exon 20 Insertion Mutations
Drug: Furmonertinib
Previously treated NSCLC Patients with HER2 Exon 20 Insertion Mutations
Drug: Furmonertinib
Previously treated NSCLC Patients with EGFR Activating Mutations, who are not eligible for Cohorts 1 and 4
Drug: Furmonertinib
Untreated or Previously treated EGFR TKI Naïve NSCLC Patients with EGFR Uncommon Mutations, excluding EGFR exon 20 insertion mutations
Drug: Furmonertinib
Furmonertinib tablet
Also known as: AST2818
Furmonertinib tablet
Also known as: AST2818
Furmonertinib tablet
Also known as: AST2818
Furmonertinib tablet
Also known as: AST2818
Furmonertinib tablet
Also known as: AST2818
Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib
Time frame: Up to 36 months after first dose
Stage 2: Overall Response Rate (ORR)
Time frame: Up to 36 months after first dose
Stage 1: Overall Response Rate
Time frame: Up to 36 months after first dose
Stage 1: Duration of Response (DOR)
Time frame: Up to 36 months after first dose
Stage 1: Disease Control Rate
Time frame: Up to 36 months after first dose
Stage 1: Progression Free Survival
Time frame: Up to 36 months after first dose
Stage 1: Depth of Response
Time frame: Up to 36 months after first dose
Stage 1: Overall survival
Time frame: Up to 36 months after first dose
Stage 1: Central Nervous System ORR
Time frame: Up to 36 months after first dose
Stage 1: Central Nervous System DOR
Time frame: Up to 36 months after first dose
Stage 1: Plasma concentrations of furmonertinib and its major metabolite (AST5902)
Time frame: Up to 36 months after first dose
Stage 1, Cohort 1, Backfill only: Plasma concentrations of furmonertinib and its major metabolite (AST5902)
Time frame: Up to 36 months after first dose
Stage 1, Cohort 1, Backfill only: Plasma concentrations of midazolam and its metabolite (1-OH-midazolam)
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Duration of Response
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Disease Control Rate
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Progression Free Survival
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Depth of Response
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Overall survival
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Central Nervous System ORR
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Central Nervous System DOR
Time frame: Up to 36 months after first dose
Stage 2, Cohort 4 only: Overall Response Rate
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Number of incidence and severity of AEs as a measure of safety and tolerability of Furmonertinib
Time frame: Up to 36 months after first dose
Stage 2, all cohorts: Plasma concentrations of furmonertinib and its major metabolite (AST5902)
Time frame: Up to 36 months after first dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Jun 2025, 35 months.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 35 months is below that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflutinib
Carcinoma, Non-Small-Cell Lung →
ArriVent BioPharma, Inc.